First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.

We aimed to study the associations between androgen-deprivation therapy (ADT)-induced weight changes and prostate cancer (PC) progression and mortality in men who had undergone radical prostatectomy (RP).

Data from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort were used to study the associations between weight change approximately 1-year post-ADT initiation and metastases, castration-resistant prostate cancer (CRPC), all-cause mortality (ACM), and PC-specific mortality (PCSM) in 357 patients who had undergone RP between 1988 and 2014. We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) using covariate-adjusted Cox regression models for associations between weight loss, and weight gains of 2.3 kg or more, and PC progression and mortality post-ADT.

During a median (IQR) follow-up of 81 (46-119) months, 55 men were diagnosed with metastases, 61 with CRPC, 36 died of PC, and 122 died of any cause. In multivariable analysis, weight loss was associated with increases in risks of metastases (HR 3.13; 95% CI 1.40-6.97), PCSM (HR 4.73; 95% CI 1.59-14.0), and ACM (HR 2.16; 95% CI 1.25-3.74) compared with mild weight gains of ≤ 2.2. Results were slightly attenuated but remained statistically significant in analyses that accounted for competing risks of non-PC death. Estimates for the associations between weight gains of ≥ 2.3 kg and metastases (HR 1.58; 95% CI 0.73-3.42), CRPC (HR 1.33; 95% CI 0.66-2.66), and PCSM (HR 2.44; 95% CI 0.84-7.11) were elevated, but not statistically significant.

Our results suggest that weight loss following ADT initiation in men who have undergone RP is a poor prognostic sign. If confirmed in future studies, testing ways to mitigate weight loss post-ADT may be warranted.

Cancer causes & control : CCC. 2019 Jan 30 [Epub ahead of print]

Kagan Griffin, Ilona Csizmadi, Lauren E Howard, Gina-Maria Pomann, William J Aronson, Christopher J Kane, Christopher L Amling, Matthew R Cooperberg, Martha K Terris, Jennifer Beebe-Dimmer, Stephen J Freedland

Urology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA., Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA., Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA., Department of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA, USA., Division of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA, USA., Division of Urology, Department of Surgery, Oregon Health & Science University, Portland, OR, USA., Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA., Urology Section, Division of Surgery, Veterans Affairs Medical Center and Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA, USA., Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA., Urology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe